A study of luspatercept versus standard-of-care in the first-line treatment setting for myelodysplastic syndromes (MDS) patients.

Trial Profile

A study of luspatercept versus standard-of-care in the first-line treatment setting for myelodysplastic syndromes (MDS) patients.

Planning
Phase of Trial: Phase III

Latest Information Update: 07 Nov 2017

At a glance

  • Drugs Luspatercept (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Acronyms COMMANDS
  • Most Recent Events

    • 07 Nov 2017 According to an Acceleron media release, this trial is expected to begin in the 1H 2018.
    • 02 May 2017 New trial record
    • 27 Apr 2017 According to an Acceleron media release, the company expects to initiate this study in early 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top